P. Deprez

发表

Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

E. Mandine, G. Lange, P. Broto, 2003, Journal of medicinal chemistry.

Cobalt and molybdenum carbonyl clusters in immunology. Synthesis and binding properties of mycotoxin derivatives of zearalenone

A. Vessières, G. Jaouen, D. Thouvenot, 1989 .

Src homology‐2 domain binding assays by scintillation proximity and surface plasmon resonance

E. Mandine, D. Lesuisse, P. Deprez, 2001, Journal of molecular recognition : JMR.

SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2.

Jean-Pierre Marquette, E. Mandine, G. Lange, 2002, Journal of medicinal chemistry.

Isolated bilateral transverse agenesis of the distal segments of the lower limbs at the level of the knee joint in a human fetus

Y. Gillerot, M. Vikkula, C. Godfraind, 2016, American journal of medical genetics. Part A.

Discovery of diarylhydantoins as new selective androgen receptor modulators.

T. Prangé, N. Triballeau, D. Guédin, 2012, Journal of medicinal chemistry.

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.

L. Nelles, S. Dupont, N. Triballeau, 2014, Journal of medicinal chemistry.

Discovery of 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.

L. Nelles, G. Milligan, S. Dupont, 2020, Journal of medicinal chemistry.

Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.

L. Nelles, R. Geney, E. M. van der Aar, 2014, Journal of medicinal chemistry.

No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions.

E. Casanova, M. Gassmann, B. Bettler, 2008, Journal of molecular endocrinology.

Regio- and stereoselective reduction of bicyclic imides for the asymmetric synthesis of highly substituted pyrrolidines

J. Royer, P. Deprez, H. Husson, 1993 .

Pharmacological characterization of GLPG1972/S201086, a potent and selective small molecule inhibitor of ADAMTS5.

Margaret M. Smith, C. Little, F. De Ceuninck, 2021, Osteoarthritis and cartilage.

Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding.

T. T. Duc, E. Mandine, G. Lange, 2001, Bioorganic & medicinal chemistry letters.

Thiol inhibitors of endothelin-converting enzyme

J. Dumas, P. Deprez, J. Guillaume, 1996 .

Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.

E. Mandine, G. Lange, B. Schoot, 2002, Bioorganic & medicinal chemistry letters.

Discovery of thioazepinone ligands for Src SH2: from non-specific to specific binding.

T. T. Duc, E. Mandine, G. Lange, 2001, Bioorganic & medicinal chemistry letters.

DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose.

P. Tsvetkov, A. Makarov, V. Lamour, 2002, Biochemistry.

Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl)sulfonylurea (HR 720).

H. Heitsch, M. Fortin, G. Hamon, 1995, Journal of medicinal chemistry.

Efficient Two-Step Syntheses of Sulfonylguanidines from Sulfonamides

P. Deprez, J. Vevert, 1996 .

High diastereofacial selectivity in the 1,3-dipolar cycloaddition of chiral azomethine ylides

J. Royer, P. Deprez, H. Husson, 1991 .

A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.

Akira Yamaguchi, Kazuhiro Aoki, Roland Baron, 2006, The Journal of clinical investigation.

Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism.

S. Morony, K. Pattabiraman, J. Reagan, 2013, Bioorganic & medicinal chemistry letters.

New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas.

D. Guédin, P. Deprez, M. Auberval, 2013, Bioorganic & medicinal chemistry letters.

Molecular Study of a Hoxa2 Gain-of-Function in Chondrogenesis: A Model of Idiopathic Proportionate Short Stature

B. Lengelé, C. Nyssen-Behets, P. Deprez, 2013, International journal of molecular sciences.

EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex

N. Crapoulet, R. Ouellette, S. M. Lewis, 2021, Scientific Reports.

Purification and amino acid sequence of human motilin isolated from a motilin containing liver metastasis

G. Assche, I. Depoortere, T. Peeters, 1995, Regulatory Peptides.

Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein.

E. Mandine, Eliane Mandine, D. Lesuisse, 2002, Bioorganic & medicinal chemistry letters.

Imidazole-based ligands of the Src SH2 protein.

E. Mandine, D. Lesuisse, P. Deprez, 2002, Bioorganic & medicinal chemistry letters.

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

N. Triballeau, E. M. van der Aar, T. Christophe, 2021, Journal of medicinal chemistry.

GLPG1972: a potent, selective, orally available adamts-5 inhibitor for the treatment of OA

C. Little, T. Christophe, P. Mollat, 2017 .

Synthesis of difluoromethylthio imidazole from methylthio imidazole

P. Deprez, J. Vevert, 1996 .

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.

N. Triballeau, D. Guédin, J. Feyen, 2012, Journal of medicinal chemistry.

Postnatal growth defect in mice upon persistent Hoxa2 expression in the chondrogenic cell lineage.

D. Chappard, J. Devogelaer, B. Lengelé, 2012, Differentiation; research in biological diversity.

Balanced AT1 and AT2 angiotensin II antagonists. I. New orally active 5-carboxyl imidazolyl biphenyl sulfonylureas

M. Fortin, P. Deprez, A. Corbier, 1995 .

Balanced AT1 and AT2 Angiotensin II Antagonists. Part 1. New Orally Active 5-Carboxyl Imidazolyl Biphenyl Sulfonylureas

M. Fortin, P. Deprez, A. Corbier, 1996 .

Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureas

M. Fortin, P. Deprez, A. Corbier, 1995 .

Balanced AT1 and AT2 angiotensin II antagonists. III. potent and orally active 5-β-ketosulfoxide imidazolyl biphenyl sulfonylureas

M. Fortin, P. Deprez, A. Corbier, 1995 .

New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas.

D. Guédin, P. Deprez, M. Auberval, 2013, Bioorganic & medicinal chemistry letters.

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.

N. Triballeau, D. Guédin, J. Feyen, 2012, Journal of medicinal chemistry.